首页> 外文期刊>Journal of clinical and experimental hematopathology : >Composite Lymphoma as Co-occurrence of Advanced Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Carrying Trisomy 12 and t(14;18) and Peripheral T-cell Lymphoma
【24h】

Composite Lymphoma as Co-occurrence of Advanced Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Carrying Trisomy 12 and t(14;18) and Peripheral T-cell Lymphoma

机译:复合性淋巴瘤与晚期慢性淋巴细胞白血病/携带三体性12和t(14; 18)的小淋巴细胞淋巴瘤和周围T细胞淋巴瘤同时存在

获取原文
           

摘要

Composite lymphoma is defined as the co-occurrence of two types of lymphoma, comprising 1-4% of lymphomas, and the association of B-cell-type chronic lymphocytic leukemia (B-CLL)/small lymphocytic lymphoma and peripheral T-cell lymphoma (PTCL) is rare. Here, we report a case (77-year-old woman) of advanced B-CLL complicated by newly appearing PTCL. Two years after the onset of B-CLL, CLL cells acquired CD38 antigen expression and the disease entity became CLL/prolymphocytic leukemia. Trisomy 12 and t(14;18) karyotypes were observed. Five years after the onset of B-CLL, large abnormal cells with convoluted nuclei appeared in the peripheral blood and rapidly increased in number. These cells were positive for CD3, CD4, CD5, CD30 (partially), CD56, and αβ-type T-cell receptor (TCR), in which PCR demonstrated monoclonal TCR-γ gene rearrangement. An additional diagnosis of PTCL, not otherwise specified was made. We treated her with an R-CHOP regimen, resulting in the marked reduction of B-CLL cells but progressive PTCL. Brentuximab vedotin had a transient effect, but the patient died of sepsis due to residual PTCL and pancytopenia. This case is highly informative for tumor biology of B-CLL in terms of emergence of both chromosomal abnormalities and PTCL with progression of this leukemia.
机译:复合性淋巴瘤定义为两种类型的淋巴瘤并发,包括1-4%的淋巴瘤,以及B细胞型慢性淋巴细胞白血病(B-CLL)/小淋巴细胞淋巴瘤和周围性T细胞淋巴瘤的关联(PTCL)很罕见。在此,我们报告了一例(77岁女性)晚期B-CLL并发新出现的PTCL并发的情况。 B-CLL发作两年后,CLL细胞获得了CD38抗原表达,疾病实体变为CLL /淋巴细胞性白血病。观察到三体性12和t(14; 18)核型。 B-CLL发作后的五年,外周血中出现了具有扭曲核的大异常细胞,并且数量迅速增加。这些细胞对CD3,CD4,CD5,CD30(部分),CD56和αβ型T细胞受体(TCR)呈阳性,其中PCR显示单克隆TCR-γ基因重排。进行了PTCL的其他诊断,未另行说明。我们用R-CHOP方案治疗了她,导致B-CLL细胞明显减少,但进行性PTCL减少。 Brentuximab vedotin具有短暂作用,但患者因残留PTCL和全血细胞减少症而死于败血症。从这种白血病的进展来看,染色体异常和PTCL的出现对于B-CLL的肿瘤生物学来说都是非常有用的信息。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号